The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use. ⋯ Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; Caravaggio ClinicalTrials.gov number, NCT03045406.).
-
Letter Case Reports
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.